133 related articles for article (PubMed ID: 25043451)
1. (G12D) NRAS and kinase-dead BRAF cooperate to drive naevogenesis and melanomagenesis.
Pedersen M; Viros A; Cook M; Marais R
Pigment Cell Melanoma Res; 2014 Nov; 27(6):1162-6. PubMed ID: 25043451
[No Abstract] [Full Text] [Related]
2. A Transcriptionally Inactive ATF2 Variant Drives Melanomagenesis.
Claps G; Cheli Y; Zhang T; Scortegagna M; Lau E; Kim H; Qi J; Li JL; James B; Dzung A; Levesque MP; Dummer R; Hayward NK; Bosenberg M; Brown KM; Ronai ZA
Cell Rep; 2016 May; 15(9):1884-92. PubMed ID: 27210757
[TBL] [Abstract][Full Text] [Related]
3. Melanocytic nevus-like hyperplasia and melanoma in transgenic BRAFV600E mice.
Goel VK; Ibrahim N; Jiang G; Singhal M; Fee S; Flotte T; Westmoreland S; Haluska FS; Hinds PW; Haluska FG
Oncogene; 2009 Jun; 28(23):2289-98. PubMed ID: 19398955
[TBL] [Abstract][Full Text] [Related]
4. Abrogation of BRAFV600E-induced senescence by PI3K pathway activation contributes to melanomagenesis.
Vredeveld LC; Possik PA; Smit MA; Meissl K; Michaloglou C; Horlings HM; Ajouaou A; Kortman PC; Dankort D; McMahon M; Mooi WJ; Peeper DS
Genes Dev; 2012 May; 26(10):1055-69. PubMed ID: 22549727
[TBL] [Abstract][Full Text] [Related]
5. Ultraviolet radiation accelerates BRAF-driven melanomagenesis by targeting TP53.
Viros A; Sanchez-Laorden B; Pedersen M; Furney SJ; Rae J; Hogan K; Ejiama S; Girotti MR; Cook M; Dhomen N; Marais R
Nature; 2014 Jul; 511(7510):478-482. PubMed ID: 24919155
[TBL] [Abstract][Full Text] [Related]
6. RAF proteins exert both specific and compensatory functions during tumour progression of NRAS-driven melanoma.
Dorard C; Estrada C; Barbotin C; Larcher M; Garancher A; Leloup J; Beermann F; Baccarini M; Pouponnot C; Larue L; Eychène A; Druillennec S
Nat Commun; 2017 May; 8():15262. PubMed ID: 28497782
[TBL] [Abstract][Full Text] [Related]
7. ROS production induced by BRAF inhibitor treatment rewires metabolic processes affecting cell growth of melanoma cells.
Cesi G; Walbrecq G; Zimmer A; Kreis S; Haan C
Mol Cancer; 2017 Jun; 16(1):102. PubMed ID: 28595656
[TBL] [Abstract][Full Text] [Related]
8. Inactivation of the Hippo tumor suppressor pathway promotes melanoma.
Vittoria MA; Kingston N; Kotynkova K; Xia E; Hong R; Huang L; McDonald S; Tilston-Lunel A; Darp R; Campbell JD; Lang D; Xu X; Ceol CJ; Varelas X; Ganem NJ
Nat Commun; 2022 Jun; 13(1):3732. PubMed ID: 35768444
[TBL] [Abstract][Full Text] [Related]
9. C-MYC overexpression is required for continuous suppression of oncogene-induced senescence in melanoma cells.
Zhuang D; Mannava S; Grachtchouk V; Tang WH; Patil S; Wawrzyniak JA; Berman AE; Giordano TJ; Prochownik EV; Soengas MS; Nikiforov MA
Oncogene; 2008 Nov; 27(52):6623-34. PubMed ID: 18679422
[TBL] [Abstract][Full Text] [Related]
10. Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF.
Heidorn SJ; Milagre C; Whittaker S; Nourry A; Niculescu-Duvas I; Dhomen N; Hussain J; Reis-Filho JS; Springer CJ; Pritchard C; Marais R
Cell; 2010 Jan; 140(2):209-21. PubMed ID: 20141835
[TBL] [Abstract][Full Text] [Related]
11. Elucidating distinct roles for NF1 in melanomagenesis.
Maertens O; Johnson B; Hollstein P; Frederick DT; Cooper ZA; Messiaen L; Bronson RT; McMahon M; Granter S; Flaherty K; Wargo JA; Marais R; Cichowski K
Cancer Discov; 2013 Mar; 3(3):338-49. PubMed ID: 23171796
[TBL] [Abstract][Full Text] [Related]
12. KIT Suppresses BRAF
Neiswender JV; Kortum RL; Bourque C; Kasheta M; Zon LI; Morrison DK; Ceol CJ
Cancer Res; 2017 Nov; 77(21):5820-5830. PubMed ID: 28947418
[TBL] [Abstract][Full Text] [Related]
13. High BRAF mutation frequency does not characterize all melanocytic tumor types.
Saldanha G; Purnell D; Fletcher A; Potter L; Gillies A; Pringle JH
Int J Cancer; 2004 Sep; 111(5):705-10. PubMed ID: 15252839
[TBL] [Abstract][Full Text] [Related]
14. CDKN2B Loss Promotes Progression from Benign Melanocytic Nevus to Melanoma.
McNeal AS; Liu K; Nakhate V; Natale CA; Duperret EK; Capell BC; Dentchev T; Berger SL; Herlyn M; Seykora JT; Ridky TW
Cancer Discov; 2015 Oct; 5(10):1072-85. PubMed ID: 26183406
[TBL] [Abstract][Full Text] [Related]
15. Progression of NRAS and BRAF mutations in cutaneous melanoma.
Rosso R; Romagosa Y; Kirsner RS
J Invest Dermatol; 2009 Jun; 129(6):1318. PubMed ID: 19434085
[No Abstract] [Full Text] [Related]
16. Usp9x regulates Ets-1 ubiquitination and stability to control NRAS expression and tumorigenicity in melanoma.
Potu H; Peterson LF; Kandarpa M; Pal A; Sun H; Durham A; Harms PW; Hollenhorst PC; Eskiocak U; Talpaz M; Donato NJ
Nat Commun; 2017 Feb; 8():14449. PubMed ID: 28198367
[TBL] [Abstract][Full Text] [Related]
17. Ppp6c haploinsufficiency accelerates UV-induced BRAF(V600E)-initiated melanomagenesis.
Kanazawa K; Kishimoto K; Nomura M; Kurosawa K; Kato H; Inoue Y; Miura K; Fukui K; Yamashita Y; Sato I; Tsuji H; Watanabe T; Tanaka T; Yasuda J; Tanuma N; Shima H
Cancer Sci; 2021 Jun; 112(6):2233-2244. PubMed ID: 33743547
[TBL] [Abstract][Full Text] [Related]
18. PIK3CA-mutated melanoma cells rely on cooperative signaling through mTORC1/2 for sustained proliferation.
Silva JM; Deuker MM; Baguley BC; McMahon M
Pigment Cell Melanoma Res; 2017 May; 30(3):353-367. PubMed ID: 28233937
[TBL] [Abstract][Full Text] [Related]
19. Clinical outcome and pathological features associated with NRAS mutation in cutaneous melanoma.
Devitt B; Liu W; Salemi R; Wolfe R; Kelly J; Tzen CY; Dobrovic A; McArthur G
Pigment Cell Melanoma Res; 2011 Aug; 24(4):666-72. PubMed ID: 21615881
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of melanoma development in the Nras((Q61K)) ::Ink4a(-/-) mouse model by the small molecule BI-69A11.
Feng Y; Lau E; Scortegagna M; Ruller C; De SK; Barile E; Krajewski S; Aza-Blanc P; Williams R; Pinkerton AB; Jackson M; Chin L; Pellecchia M; Bosenberg M; Ronai ZA
Pigment Cell Melanoma Res; 2013 Jan; 26(1):136-42. PubMed ID: 23035722
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
